[{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"593b542b-470d-465e-ae6a-8f9b079a6849","acronym":"ALLIANCE-ABTC-1604","url":"https://clinicaltrials.gov/study/NCT03107780","created_at":"2021-01-18T15:18:36.892Z","updated_at":"2025-02-25T13:48:22.462Z","phase":"Phase 1","brief_title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","source_id_and_acronym":"NCT03107780 - ALLIANCE-ABTC-1604","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 02/07/2026","study_completion_date":" 02/07/2026","last_update_posted":"2025-02-21"},{"id":"4bdac475-2ce7-43c7-9fc6-1b82deed752b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376800","created_at":"2022-05-17T12:54:19.363Z","updated_at":"2025-02-25T14:08:51.835Z","phase":"Phase 1","brief_title":"A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma","source_id_and_acronym":"NCT05376800","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type • IDH wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/07/2022","start_date":" 11/07/2022","primary_txt":" Primary completion: 08/29/2025","primary_completion_date":" 08/29/2025","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2025-02-18"},{"id":"e403d404-bc05-4817-9ff3-f97c2077e32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03449381","created_at":"2021-01-18T17:00:34.045Z","updated_at":"2025-02-25T14:15:08.572Z","phase":"Phase 1","brief_title":"This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)","source_id_and_acronym":"NCT03449381","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-18"},{"id":"c9d1a579-ede0-4060-a970-738063622323","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654716","created_at":"2021-01-18T17:56:08.387Z","updated_at":"2025-02-25T14:40:01.342Z","phase":"Phase 1","brief_title":"Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer","source_id_and_acronym":"NCT03654716","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • MDM2 • TET2 • SMARCB1 • PPM1D","pipe":" | ","alterations":" TP53 wild-type • TET2 mutation","tags":["TP53 • MDM2 • TET2 • SMARCB1 • PPM1D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2025-02-14"},{"id":"a3330799-3a3c-4c3b-bada-534a183f734f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05382338","created_at":"2022-05-19T11:56:15.604Z","updated_at":"2025-02-25T15:12:50.886Z","phase":"Phase 3","brief_title":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","source_id_and_acronym":"NCT05382338","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN • GLI2","pipe":" | ","alterations":" TP53 wild-type","tags":["MYCN • GLI2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • vincristine • lomustine • mesna"],"overall_status":"Suspended","enrollment":" Enrollment 225","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 12/20/2027","primary_completion_date":" 12/20/2027","study_txt":" Completion: 12/20/2027","study_completion_date":" 12/20/2027","last_update_posted":"2025-02-13"},{"id":"9518cf2f-a488-48b8-a437-c584bd916e0c","acronym":"Brightline-2","url":"https://clinicaltrials.gov/study/NCT05512377","created_at":"2022-08-23T14:55:35.585Z","updated_at":"2025-02-25T15:19:58.742Z","phase":"Phase 2","brief_title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","source_id_and_acronym":"NCT05512377 - Brightline-2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-11"},{"id":"d1947b42-42fd-4782-93fd-228a17b831b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05372367","created_at":"2022-05-12T14:59:38.525Z","updated_at":"2025-02-25T16:39:01.449Z","phase":"Phase 1","brief_title":"A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor","source_id_and_acronym":"NCT05372367","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • itraconazole • rifampicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 07/17/2024","primary_completion_date":" 07/17/2024","study_txt":" Completion: 06/13/2025","study_completion_date":" 06/13/2025","last_update_posted":"2025-02-07"},{"id":"6fb8e6bc-6843-426e-b257-f87a181c8030","acronym":"","url":"https://clinicaltrials.gov/study/NCT04855695","created_at":"2021-04-22T20:53:44.057Z","updated_at":"2025-02-25T14:59:49.341Z","phase":"Phase 1/2","brief_title":"Avo In R/R And Previously Untreated MCL","source_id_and_acronym":"NCT04855695","lead_sponsor":"Austin I Kim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-29"},{"id":"9795b4cb-6f73-4ce5-a9a8-6ba8acc8d386","acronym":"Keynote MK-3475-B66","url":"https://clinicaltrials.gov/study/NCT03611868","created_at":"2021-01-18T17:45:12.835Z","updated_at":"2025-02-25T16:08:10.551Z","phase":"Phase 1/2","brief_title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","source_id_and_acronym":"NCT03611868 - Keynote MK-3475-B66","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" ATM mutation • TP53 wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-07-19"},{"id":"69e83241-ea93-4a7c-a2c5-2fc40b9cacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03964233","created_at":"2021-01-18T19:30:14.916Z","updated_at":"2024-07-02T16:34:27.457Z","phase":"Phase 1","brief_title":"A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)","source_id_and_acronym":"NCT03964233","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/03/2024","primary_completion_date":" 09/03/2024","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-06-11"},{"id":"8c5b3516-4a7c-4205-ad40-e97eec56da64","acronym":"","url":"https://clinicaltrials.gov/study/NCT03940352","created_at":"2021-01-18T19:24:11.865Z","updated_at":"2024-07-02T16:34:27.521Z","phase":"Phase 1","brief_title":"HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT03940352","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • sabatolimab (MBG453) • siremadlin (HDM201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 06/14/2024","primary_completion_date":" 06/14/2024","study_txt":" Completion: 06/14/2024","study_completion_date":" 06/14/2024","last_update_posted":"2024-06-11"},{"id":"c1839cbf-613f-4d9e-a411-c798048e613b","acronym":"XPORT-EC-042","url":"https://clinicaltrials.gov/study/NCT05611931","created_at":"2022-11-10T17:01:16.763Z","updated_at":"2024-07-02T16:34:58.758Z","phase":"Phase 3","brief_title":"Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT05611931 - XPORT-EC-042","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-06-05"},{"id":"95af92d3-7ef1-42bc-8075-503c2a4324fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03975387","created_at":"2021-01-18T19:33:08.305Z","updated_at":"2024-07-02T16:35:05.855Z","phase":"Phase 1/2","brief_title":"Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53","source_id_and_acronym":"NCT03975387","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASTX295"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-06"},{"id":"4d2d76d4-435a-440f-8e0e-92bf66cb6dca","acronym":"NRG-GY019","url":"https://clinicaltrials.gov/study/NCT04095364","created_at":"2021-01-18T20:02:20.500Z","updated_at":"2024-07-02T16:35:06.502Z","phase":"Phase 3","brief_title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04095364 - NRG-GY019","lead_sponsor":"NRG Oncology","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-05-02"},{"id":"d1c65fef-f151-4887-8cfe-4cca4bc9b521","acronym":"","url":"https://clinicaltrials.gov/study/NCT03282396","created_at":"2021-01-18T16:12:27.906Z","updated_at":"2024-07-02T16:35:08.356Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma","source_id_and_acronym":"NCT03282396","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-04-22"},{"id":"8626d796-d31d-4f11-a4ab-8ea3dce4cf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT03725436","created_at":"2021-01-18T18:15:21.875Z","updated_at":"2024-07-02T16:35:08.781Z","phase":"Phase 1","brief_title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","source_id_and_acronym":"NCT03725436","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A","pipe":" | ","alterations":" ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification","tags":["HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sulanemadlin (ALRN-6924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-18"},{"id":"23fbfd55-0bea-4321-83e6-d320991b3c5c","acronym":"AMPHISARC","url":"https://clinicaltrials.gov/study/NCT05180695","created_at":"2022-01-06T22:53:30.960Z","updated_at":"2025-02-25T15:54:18.762Z","phase":"Phase 1/2","brief_title":"HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas","source_id_and_acronym":"NCT05180695 - AMPHISARC","lead_sponsor":"Centre Leon Berard","biomarkers":" MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-04-08"},{"id":"ba5e9c1f-9156-4368-acb2-f775396afb8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04029688","created_at":"2021-01-18T19:46:44.421Z","updated_at":"2024-07-02T16:35:12.360Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","source_id_and_acronym":"NCT04029688","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • cyclophosphamide • topotecan • idasanutlin (RG7388) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-03-29"},{"id":"cb935a08-f353-4653-b5c2-b1bea0cd347d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05538572","created_at":"2022-09-14T18:56:05.720Z","updated_at":"2024-07-02T16:35:23.135Z","phase":"Phase 1","brief_title":"A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05538572","lead_sponsor":"Prelude Therapeutics","biomarkers":" HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B","pipe":" | ","alterations":" KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type","tags":["HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRT3645"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-17"},{"id":"41dc0dc5-5e4a-4f14-83b1-f68418f88664","acronym":"","url":"https://clinicaltrials.gov/study/NCT02965950","created_at":"2021-01-18T14:34:42.467Z","updated_at":"2024-07-02T16:35:23.603Z","phase":"Phase 2","brief_title":"The p53 Breast Cancer Trial","source_id_and_acronym":"NCT02965950","lead_sponsor":"Haukeland University Hospital","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" TP53 mutation • HR positive • HER-2 negative • TP53 wild-type • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HR positive • HER-2 negative • TP53 wild-type • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2024-01-12"},{"id":"f98339f3-8da6-4706-ab29-7a338e6db7fa","acronym":"TTI-622-01","url":"https://clinicaltrials.gov/study/NCT03530683","created_at":"2021-07-15T16:53:02.099Z","updated_at":"2024-07-02T16:35:25.423Z","phase":"Phase 1","brief_title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","source_id_and_acronym":"NCT03530683 - TTI-622-01","lead_sponsor":"Pfizer","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 09/11/2024","primary_completion_date":" 09/11/2024","study_txt":" Completion: 09/11/2024","study_completion_date":" 09/11/2024","last_update_posted":"2023-12-22"},{"id":"aa1cebd7-d5ff-467e-9ba4-a573015d172c","acronym":"PersoMed-I","url":"https://clinicaltrials.gov/study/NCT04402073","created_at":"2021-01-18T21:14:10.343Z","updated_at":"2024-07-02T16:35:26.623Z","phase":"Phase 2","brief_title":"Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma","source_id_and_acronym":"NCT04402073 - PersoMed-I","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" TP53 • BRCA2 • MYCN","pipe":" | ","alterations":" TP53 wild-type • MYCN amplification","tags":["TP53 • BRCA2 • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • vincristine • lomustine • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2023-12-11"},{"id":"96a72c38-5254-4a8a-8d13-048c6238a111","acronym":"EMPIRE","url":"https://clinicaltrials.gov/study/NCT06084689","created_at":"2023-10-16T15:12:55.518Z","updated_at":"2024-07-02T16:35:32.276Z","phase":"Phase 2","brief_title":"Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures","source_id_and_acronym":"NCT06084689 - EMPIRE","lead_sponsor":"Institut Bergonié","biomarkers":" PD-L1 • TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["PD-L1 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-10-20"}]